Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Senores Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹1,048.00
High
₹1,194.40
Price Summary
| Previous Close | ₹1,129.50 |
|---|---|
| Day's Range | ₹1,048.00 - ₹1,194.40 |
| Open | ₹1,049.90 |
| 52 Week Range | ₹491.00 - ₹1,063.80 |
| Volume | 45,97,449 |
| Market Cap | ₹0.01 |
| Previous Close | ₹1,130.05 |
|---|---|
| Day's Range | ₹1,033.05 - ₹1,193.35 |
| Open | ₹1,033.05 |
| 52 Week Range | ₹491.00 - ₹1,062.00 |
| Volume | 2,46,970 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 51,928.19 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 45.11 |
| TTM EPS (₹) | 25.05 |
| P/E Ratio | 45.04 |
| Book Value(₹) | 5.57 |
| PAT Margin (%) | 14.65 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 11.94 |
| Trade Value ( ₹ in Lacs) | 2,790.88 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 45.11 |
| TTM EPS (₹) | 25.05 |
| P/E Ratio | 45.04 |
| Book Value(₹) | 5.57 |
| PAT Margin (%) | 14.65 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 11.94 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 385.4 | 118.6 |
| Expenses | N/A | N/A |
| PBT | 51.1 | 29.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 36.9 | 20.2 |
About Senores Pharmaceuticals Ltd.
| Founded | 2017 |
|---|---|
| Managing Director | Swapnil Jatinbhai Shah |
| NSE Symbol | SENORES |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,57,121.30 | 1,905.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,81,396.01 | 6,818.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,48,729.85 | 4,394.35 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,15,331.11 | 8,028.70 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,240.83 | 1,426.60 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,11,126.23 | 1,329.30 | 1,148.40 - 1,148.40 |
| Mankind Pharma Ltd. | 1,03,056.40 | 2,504.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,03,022.72 | 1,060.00 | 903.00 - 903.00 |
| Lupin Ltd. | 1,03,010.73 | 2,248.00 | 1,836.80 - 1,836.80 |
| Zydus Lifesciences Ltd. | 99,737.91 | 991.20 | 835.50 - 835.50 |
No Records Found
Latest News
Senores Pharmaceuticals informs about press release
Senores Pharmaceuticals informs about media release
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Senores Pharmaceuticals has informed that it enclosed a copy of Media Release being issued by the Company on ‘Senores Pharmaceuticals, Inc. announces Strategic Joint Venture in the United States, positioning the group for U.S. Federal and Defense Sector Supplies’. The same is also being uploaded on the website of the Company at www.senorespharma.com.
The above information is a part of company’s filings submitted to BSE.
Senores Pharmaceuticals informs about analyst meet
Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, Senores Pharmaceuticals has informed that the officials of the Company will be meeting Analysts/ Investors at its Corporate Office situated in Ahmedabad, Gujarat as per the details enclosed. Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.
The above information is a part of company’s filings submitted to BSE.
Aarti Drugs informs about newspaper publication
Fortis Malar Hospitals informs about outcome of board meeting
Pursuant to the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 (‘SEBI Listing Regulations’) Fortis Malar Hospitals has informed that the Board of Directors of the Company at its meeting held today, Monday, May 18, 2026, considered and approved the following: - 1. Financial Results: Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026 along with Statement of Assets and Liabilities as on March 31, 2026. B S R & Co. LLP, the Statutory Auditors of the Company have issued an Audit Report with an unmodified opinion on the Standalone and Consolidated Financial Statements. Accordingly, the standalone and consolidated audited financial results, auditors’ reports, Statement of Assets & Liabilities, and declaration pursuant to Regulation 33(3)(d) of the SEBI Listing Regulations, regarding Unmodified Opinion on the Audited financial results for the financial year ended March 31, 2026 are enclosed; 2. Adoption of Policies: a. The modification in the policy for the determination of Materiality of Events/Information, which also contains the details of persons authorized to determine the Materiality of the Event/Information for the purpose of disclosures to Stock Exchange. The said revised policy has been enclosed. b. The updated Policy/Code of Conduct for the prevention of Insider Trading. The said updated policy/Code has also been enclosed. The Board Meeting commenced at 11:30 am (IST) and concluded at 03:35 pm (IST). The same is also uploaded on the website of the Company.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Senores Pharmaceuticals Ltd. is ₹1,129.50 as of 2026-05-18.
The market capitalisation of Senores Pharmaceuticals Ltd. is ₹5,204.29 as of 2026-05-18.
The 1-year return of Senores Pharmaceuticals Ltd. is 0.00% as of 2026-05-18.
The P/E ratio of Senores Pharmaceuticals Ltd. is 45.04 as of 2026-05-18.
The 52-week high and low of Senores Pharmaceuticals Ltd. are ₹1,063.80 and ₹491.00, respectively, as of 2026-05-18.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
